



PEARL

Human Endogenous Retrovirus Type K promotes proliferation of Merlin-negative schwannoma and meningioma which can be inhibited by anti-retroviral and anti-TEAD drugs

Hanemann, CO; Maze, E; Agit, B; Reeves, S; Hilton, D; Parkinson, DB; Laraba, L; Ercolano, E; Kurian, K; Belshaw, R; Ammoun, S

DOI:

[10.14791/btrt.2022.10.f-1131](https://doi.org/10.14791/btrt.2022.10.f-1131)

Publication date:

2022

Link:

[Link to publication in PEARL](#)

Citation for published version (APA):

Hanemann, CO., Maze, E., Agit, B., Reeves, S., Hilton, D., Parkinson, DB., Laraba, L., Ercolano, E., Kurian, K., Belshaw, R., & Ammoun, S. (2022). *Human Endogenous Retrovirus Type K promotes proliferation of Merlin-negative schwannoma and meningioma which can be inhibited by anti-retroviral and anti-TEAD drugs*. <https://doi.org/10.14791/btrt.2022.10.f-1131>

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Wherever possible please cite the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

Abstract 1164: Human endogenous retrovirus type K promotes proliferation of Merlin negative schwannoma and meningioma which can be inhibited by anti-retroviral and anti-TEAD drugs

Sylwia Ammoun, Emmanuel A. Maze, Bora Agit, Robert Belshaw and C Oliver Hanemann

DOI: 10.1158/1538-7445.AM2021-1164 Published July 2021

Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA

Abstract

Deficiency of the tumor suppressor Merlin causes the development of schwannoma, meningioma and ependymoma tumors. These can occur spontaneously or in the hereditary disease Neurofibromatosis type 2 (NF2). Merlin mutations are also relevant in a variety of other tumors. Currently available treatments are surgery or radiosurgery which are only partially effective, with tumors frequently reoccurring and in case of meningioma often as a higher grade. There is an urgent need for effective drug treatments. In this study, we investigated the role of Human Endogenous Retrovirus Type K (HERV-K) and its targetability in Merlin negative schwannoma and meningioma tumors by using tissues and primary cells isolated from patients employing immunohistochemistry, immunocytochemistry, western blotting and proliferation assays.

We demonstrate that HERV-K proteins are overexpressed in Merlin negative schwannoma and all meningioma grades. Furthermore, we implicate CRL4^{DCAF1} and YAPT/EAD Hippo pathway in this overexpression and suggest that exosome transport of the HERV-K Envelope (Env) protein might contribute to schwannoma development. We also show that: (i) Ectopic overexpression of HERV-K Env in normal Schwann cells increased proliferation and upregulated the transcription factor c-Jun. Env overexpression also increased activity of the extracellular signal-regulated kinase 1/2 (pERK1/2), a known mitogenic pathway in schwannoma. (ii) An anti-Env monoclonal antibody decreased pERK1/2 and reduced proliferation of schwannoma cells. (iii) FDA-approved retroviral protease inhibitors Ritonavir, Atazanavir and Lopinavir decreased pERK1/2 and cyclin D1 and reduced proliferation of schwannoma and grade I meningioma cells.

We provide evidence for HERV-K Env contributing to the development of NF2-associated schwannomas and meningiomas. Considering the urgent need of drugs to treat NF2, we suggest the trialling of antiretroviral protease inhibitors, and consideration of anti-HERV-K Env immunotherapy, as well as TEAD-specific inhibitors in these patients. The above treatments would also be potentially beneficial for patients with other tumors caused by Merlin deficiency.

Citation Format: Sylwia Ammoun, Emmanuel A. Maze, Bora Agit, Robert Belshaw, C Oliver Hanemann. Human endogenous retrovirus type K promotes proliferation of Merlin negative schwannoma and meningioma which can be inhibited by anti-retroviral and anti-TEAD drugs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1164.

- ©2021 American Association for Cancer Research.